Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Acurx Pharmaceuticals Inc (ACXP)

Acurx Pharmaceuticals Inc (ACXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update PR Newswire - Fri Mar 13, 6:01AM CDT

STATEN ISLAND, N.Y. , March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...

ACXP : 4.28 (-5.41%)
Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection PR Newswire - Mon Mar 9, 7:01AM CDT

Acurx's Program in the Broader CDI Patient Population is Ready to Advance to Phase 3 International Clinical Trials

ACXP : 4.28 (-5.41%)
Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update PR Newswire - Mon Feb 16, 7:01AM CST

STATEN ISLAND, N.Y. , Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...

ACXP : 4.28 (-5.41%)
USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors PR Newswire - Mon Feb 2, 7:00AM CST

STATEN ISLAND, N.Y. , Feb. 2, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule...

ACXP : 4.28 (-5.41%)
New to The Street Broadcasts Nationwide Tonight on Bloomberg Television Featuring NeOnc ($NTHI), Metaterra Holdings Inc., CISO Global ($CISO), and NRx Pharmaceuticals ($NRXP) ACCESS Newswire - Sat Dec 20, 2025

Commercial sponsors are, Sustainable Green Team (SGTM) , Synergy CHC ($SNYR), DataVault AI ($DVLT),ACURX ($ACXP) ,($PETV) and Aeries Technology ($AERT)

SNYR : 1.1300 (-3.42%)
PETV : 0.7500 (unch)
NTHI : 7.53 (-4.44%)
ACXP : 4.28 (-5.41%)
AERT : 0.3051 (-6.98%)
DVLT : 0.6286 (-4.28%)
SGTM : 0.1968 (-0.46%)
New to The Street Show #702 Airs Today on Bloomberg at 6:30 PM EST ACCESS Newswire - Sat Nov 22, 2025

The show airs as sponsored programming with TV commercials by Synergy CHC, Sustainable Green Team, Laser Pharmaceuticals, and PetVivo.

RDZN : 1.0900 (-2.68%)
ACXP : 4.28 (-5.41%)
NRXP : 2.1300 (+20.34%)
AERT : 0.3051 (-6.98%)
CISO : 0.3589 (-2.23%)
Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals PR Newswire - Tue Nov 18, 2025

STATEN ISLAND, N.Y. , Nov. 18, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

ACXP : 4.28 (-5.41%)
New to The Street Airs Landmark Show #700 Today at 6:30 PM ET on Bloomberg Television ACCESS Newswire - Sat Nov 15, 2025

Featured companies include Lionscrest Advisors, DataVault AI (NASDAQ:DVLT), Pudgy Penguins (PENGU)), Peer To Peer Network (OTC:PTOP), and Acurx Pharmaceuticals (NASDAQ:ACXP).

PTOP : 0.0210 (-12.50%)
ACXP : 4.28 (-5.41%)
DVLT : 0.6286 (-4.28%)
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update PR Newswire - Wed Nov 12, 2025

STATEN ISLAND, N.Y. , Nov. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics...

ACXP : 4.28 (-5.41%)
Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens PR Newswire - Mon Nov 10, 2025

STATEN ISLAND, N.Y. , Nov. 10, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule...

ACXP : 4.28 (-5.41%)

Barchart Exclusives

The Top High-Yield Dividend Stock to Buy Now for Oil Price Protection Barchart - Tue Mar 24, 6:30PM CDT
As the situation remains tense, this high dividend-paying consumer staple company can be a prudent choice for investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.